20th Dec 2019 12:10
(Alliance News) - A cancer treatment being developed by Hutchison China MediTech Ltd has received priority status in China, the company said Friday.
The Center for Drug Evaluation at China's National Medical Products Administration has granted the priority review status to a new drug application for surufatinib.
Surufatinib is an inhibitor being developed for the treatment on advanced non-pancreatic neuroendocrine tumours.
"Surufatinib is our second drug to be granted priority review by the NMPA," says Christian Hogg, chief executive at Chi-Med.
"We are working closely with the NMPA as they review our new drug application for the treatment of non-pancreatic neuroendocrine tumours. Surufatinib being granted priority review is a positive step forward in potentially bringing this innovative drug to patients, who currently have very limited treatment options."
Surufatinib has been granted orphan drug designation by the US Food & Drug Administration.
Hutchison said 19,000 people were diagnosed with neuroendocrine tumours in the US in 2018, and another 67,600 in China.
Hutchison shares were 1.6% higher on Friday afternoon at a price of 380.00 pence each.
By George Collard; [email protected]
Copyright 2019 Alliance News Limited. All Rights Reserved.
Related Shares:
Hutchmed